Marker Therapeutics Inc (MRKR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.18-4.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MRKR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -61.7% |
| Our one-year growth estimate | diamond | -49.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MRKR — President transition
Dated 2025-11-05
Director — Kathryn Penkus Corzo: Appointment of a new director to the board.
Why it matters: Extending the cash runway is key for Marker Therapeutics to fund operations. Investors will want to see if they can secure enough cash to last through the end of 2026.
Supportive ifManagement says they have a successful funding round. This will help them have cash until 2026-Q4.
Worry ifNo funding announcements or cash runway projections fall short of 2026-Q4.
Why it matters: Extending cash runway is crucial for the company to operate through 2026-Q4.
Supportive ifManagement shares news of a successful funding round. They also cut costs to save money.
Worry ifNo news on cash runway extension. Negative cash flow is reported.
Why it matters: If sector revenue growth slows, it could impact Marker Therapeutics' performance. It shows the health of the industry.
Worry ifSector revenue growth falls below its median rate.
Less concerning ifSector revenue growth remains above its median rate.
Why it matters: The company needs to show it can increase revenue after a drop in Q1. This will help extend the cash runway.
Supportive ifQ2 revenue exceeds $751,691, showing growth from Q1.
Worry ifQ2 revenue is less than $751,691. This shows a drop continues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $679 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,932 loss on $10,000 · 49.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If the health care sector's revenue growth speeds up, it may benefit Marker Therapeutics.
Supportive ifHealth care sector revenue growth speeds up again, over 9%.
Worry ifSector revenue growth keeps slowing down, below 9%.